Zobrazeno 1 - 10
of 140
pro vyhledávání: '"Y Snir"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
T Pfeffer-Gik, L Godny, J Ollech, N Wasserberg, I White, S Cohen, Y Broitman, I Avni-Biron, H Banai, Y Snir, H Yanai, M Yackobovich Gavan, I Shimon, G Tsvetov, R Barkan, I Dotan
Publikováno v:
Journal of Crohn's and Colitis. 17:i586-i587
Background Obesity [body mass index (BMI) ≥30 kg/m2 ] prevalence in patients with inflammatory bowel diseases (IBD) ranges between 15-40%. Dual-energy x-ray absorptiometry (DEXA) is the gold standard for body composition evaluation. Patients with u
Autor:
T Pfeffer-Gik, L Godny, J Ollech, N Wasserberg, I White, R Barkan, S Cohen, I Avni-Biron, H Banai, Y Snir, H Yanai, M Yackobovich Gavan, I Shimon, G Tsvetov, Y Broitman, I Dotan
Publikováno v:
Journal of Crohn's and Colitis. 17:i696-i697
Background Low bone mineral density (BMD) is prevalent in patients with inflammatory bowel diseases (IBD), specifically Crohn's disease (CD) due to multiple factors including active inflammation, use of corticosteroids, surgeries and nutritional defi
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
O.M. Nardone, Y. Snir, J. Hodson, R. Cannatelli, N. Labarile, K. Siau, C. Hassan, H. Yanai, I. Dotan, S. Ghosh, M. Iacucci
Publikováno v:
ESGE Days 2022.
Autor:
Y Snir, J E Ollech, N Peleg, I Avni-Biron, H Eran-Banai, Y Broitman, T Sharar-Fischler, I Goren, L Zohar, I Dotan, H Yanai
Publikováno v:
Journal of Crohn's and Colitis. 17:i324-i324
Background Patients with inflammatory bowel diseases (IBD) with an increased risk of developing colorectal carcinoma should undergo periodic surveillance colonoscopies. There is no quality metric for dysplasia detection rate (DDR) in IBD surveillance
Autor:
H Yanai, T Sharar Fischler, I Goren, J Ollech, Y Snir, Y Broitman, R Barkan, T Peffer-Gik, B Raykhel, L Kutukov, A Friedeberg, M Pauker, H Eran-Banai, I Avni-Biron, I Dotan
Publikováno v:
Journal of Crohn's and Colitis. 16:i210-i211
Background There are sparse data regarding the effectiveness of novel treatment strategies for newly diagnosed patients with Crohn’s disease (CD). Data from clinical trials demonstrate 30–40% remission rates after 1-year. We aim to assess remissi
Autor:
T Konikoff, H Yanai, H Banai, I Avni-Biron, Y Snir, L Broitman, R Barkan, L Checholin, I Dotan, J Ollech
Publikováno v:
Journal of Crohn's and Colitis. 16:i463-i464
Background Data regarding sustainability of biologics in ulcerative colitis (UC) are limited. We aimed to assess sustainability of intravenous biologics used to treat UC, infliximab (IFX) and vedolizumab (VDZ), in biologic-naïve and biologic-experie
Autor:
O M Nardone, Y Snir, J Hodson, R Cannatelli, N Labarile, K Siau, C Hassan, H Yanai, I Dotan, S Ghosh, M Iacucci
Publikováno v:
Journal of Crohn's and Colitis. 16:i067-i068
Background Advanced endoscopic technologies led to significant progress in the definition of endoscopic remission of ulcerative colitis (UC), and correlate better with histological changes, compared to standard endoscopy. However, whilst studies have
Autor:
P M Eder, B Verstock, E Culver, G Dragoni, L I Kredel, A G G de Paredes, M Kaniewska, H Leibovitzh, G Oracz, D G Ribaldone, J Wypych, A Badaoui, J F Rahier, C Bezzio, P Bossuyt, K Falloon, C F Vozzo, T Jess, L Larsen, S S Olensen, T Starzyńska, M Chaparro, D Dror, P Ellul, I Gromny, K Maciejewska, N Peleg, A B G Shitrit, Ł Szwed, R Talar-Wojnarowska, Y Snir, E Zittan, I Goren
Publikováno v:
Journal of Crohn's and Colitis. 16:i301-i302
Background Autoimmune pancreatitis (AIP) is an uncommon inflammatory disorder that may accompany inflammatory bowel disease (IBD). The clinical relevance of AIP-IBD coexistence, therapeutic strategies, and long-term outcomes are scarcely known. Metho